AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of Casodex in a pediatric setting but will not be seeking an indication in this population.
Casodex is currently approved in the US at a dose of 50mg daily tablet for use in combination with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of advanced prostate cancer (metastatic stage D2).